An increased incidence of thrombosis, including pulmonary embolism, deep venous thrombosis, and arterial thrombosis, was observed in patients treated with XELJANZ in a large, ongoing post-marketing study. The Canadian Product Monograph (CPM) of XELJANZ/XELJANZ XR has recently been updated regarding the risks of thrombosis and the use of XELJANZ/XELJANZ XR.
RecallTracker